The biotech sector is brimming with opportunities that extend far beyond the much-talked-about GLP-1 weight-loss drugs, which have garnered significant attention following the 2024 European Association for the Study of Diabetes (EASD) meeting. While GLP-1 treatments, led by giants like Eli Lilly
Theratechnologies, a Quebec-based biopharmaceutical company, is currently navigating challenging waters as it faces potential disruptions in the supply of its crucial HIV medication, Egrifta SV. This drug is widely used to reduce excess abdominal fat in HIV patients suffering from lipodystrophy.
The biopharma sector has experienced a roller coaster of venture capital investments over the past decade and a half. From explosive growth driven by the COVID-19 pandemic to a more selective and strategic investment environment, the landscape continues to evolve rapidly. This article will delve
Eli Lilly has announced substantial investments to expand its manufacturing capabilities in Ireland, with over $1 billion allocated to its Limerick facility and $800 million to its site in Kinsale. These expansions aim to significantly boost production capacities for essential biologic active
Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence In a remarkable display of confidence, Jason Raleigh, a director at Zenas BioPharma, Inc. (NASDAQ: ZBIO), has made a substantial investment in the company by acquiring $15 million worth of stock. This blockbuster move not only
The launch of Richter BioLogics' state-of-the-art biopharmaceutical Current Good Manufacturing Practice (cGMP) facility in Bovenau, Germany marks a significant milestone for the company and the industry at large. Positioned as a forefront leader in advanced biopharmaceutical production, the
